New drug trial aims to tame dangerous transplant complication
NCT ID NCT05996627
Summary
This study is testing whether the drug belumosudil can help control chronic graft-versus-host disease (cGVHD), a serious complication where the donor's immune cells attack the patient's body after a stem cell transplant. The trial will enroll 82 adult patients who have early signs of cGVHD but don't yet need strong immune-suppressing drugs. Participants will randomly receive either belumosudil or a placebo pill daily for about a year to see if the drug can delay or prevent the need for additional treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Conditions
Explore the condition pages connected to this study.